Dixon Kaufman, medical director of the UW Health Transplant Center. Among 20 patients who got the kidney and cell transplants, 15 of them, including Wiederhoeft and Okey, were able to stop taking ...

WESTON, Fla. - ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a biopharmaceutical company focused on developing drugs for renal and inflammatory diseases with a current market capitalization of $1.49 ...

In contrast, 5 weeks of a high-fat diet in the bilaterally renal-denervated group did not significantly increase arterial pressure (which went from 87±3 to 90±4 mm Hg). Furthermore, the decrease in ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that an expert panel of the EU drug regulator ... and iron deficiency in adults with chronic kidney disease. Averoa, a renal-focused biopharma ...

One of No­var­tis’ most im­por­tant clin­i­cal cat­a­lysts of the year came Thurs­day, with the ac­cel­er­at­ed ap­proval in the US of its rare kid­ney dis­ease drug … ...

and Alloy Therapeutics Inc. have signed a memorandum of understanding to jointly discover and develop first-in-class renal tissue-targeting drugs. Precision medicines for chronic renal conditions ...

Alloy will deploy its bispecific antibody and genetic medicine platforms to engineer drugs that will modulate MOH-identified drug targets in specific kidney cell types. Leveraging its renal biology ...

Phase 3 results showed Empaveli reduced proteinuria by 68% and stabilized kidney function (p=0.03 ... Sales Timing For Syfovre The Prescription Drug User Fee Act (PDUFA) target action date ...